Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen.

Scandinavian journal of rheumatology

Volumn 43, Issue 3, 2014, Pages 257-258

  Moazedi Fuerst, F C ^a   Kielhauser, S M ^b   Brickmann, K ^b   Hermann, J ^b   Lutfi, A ^b   Meilinger, M ^b   Brezinschek, H P ^b   Graninger, W B ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RITUXIMAB;

DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; LETTER; LUNG FIBROSIS; MALE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PULMONARY FIBROSIS; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84902076107     PISSN: None     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.869617     Document Type: Letter

References (0)